Non Small Cell Lung Cancer - AZD9592 - EGFR mutation

Association details:

Biomarker:	EGFR mutation
Cancer:	Non Small Cell Lung Cancer
Drug:	tilatamig samrotecan (AZD9592) (Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate, c-MET-targeted antibody-drug conjugate)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: D – Preclinical

Source:

AACR 2023

Title:

5736 - AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond

Published date:

03/15/2023

Excerpt:

AZD9592 monotherapy showed activity in vivo in patient-derived xenograft (PDX) models....Responses (≥30% regression from baseline tumor volume) were observed across a wide range of clinically relevant dose levels, including a 41% response rate in EGFRm NSCLC tumors treated at the lowest tested dose of 2 mg/kg....These results demonstrate that AZD9592 has a promising efficacy and safety profile in preclinical models...